Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib with High-Dose Chemotherapy in Refractory and Relapsed Germ Cell Tumors
NCT07850973Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2027
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in germ cell tumor (GCT), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events at 1 year, Optimal dose of Olaparib/GemDC and Olaparib/CE with ASCT at 1 year and 1 more. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
olaparib
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT07850973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07850973.